Trial Profile

Efficacy and tolerability of dalbavancin for the treatment of gram-positive infection: A retrospective study

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 May 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalbavancin (Primary)
Indications Catheter infections; Gram-positive infections; Skin and soft tissue infections
Focus Adverse reactions; Expanded access; Therapeutic Use

Most Recent Events

11 May 2017 New trial record
25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com